Michaeli, Daniel Tobias; Michaeli, Thomas; Albers, Sebastian - In: The European Journal of Health Economics 25 (2023) 6, pp. 979-997
’s five special designations for drug development regarding their safety, efficacy/clinical benefit, clinical trials … breakthrough therapy) on the safety, efficacy/clinical benefit, trials, innovativeness, economic incentives, development times, and … for this uncertainty in clinical trial evidence and cost-effectiveness, the pricing and reimbursement of these drugs …